GridAI Technologies Corp.

US$5.35As of Sun 8 Nov 2026, 12:00 UTC

NASDAQ:GRDXHealthcare

Country USA

PE (Fwd) —

TSR 10Y CAGR (68.57%)

Div yield —

ROE (203.30%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM 25.88%

Mkt cap US$47.56M

ROIC (79.81%)

SE Grade™

—

Value

—

Quality

Moat

1Y Price

Reference

$5.81

—

8.69%

—

TTM

FYE 31 Dec USD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

0.160

Revenue$M

—

◌—

0.036

0.160

—

Revenue growth%

—

342.29

—

Gross margin%

—

(1813.56)

(100.00)

(1813.56)

—

(7222.78)

Operating margin%

—

(19539.98)

(100.00)

(19539.98)

—

(12789.65)

Net margin%

—

(17634.42)

(100.00)

(17634.42)

—

P/E ratio (avg)x

—

EV/EBITx

—

(23.65)

FCF yield (avg)%

—

(229.25)

(354.83)

(166.75)

(161.97)

(1.85)

(198.00)

—

(5064.95)

FCF margin%

—

(15731.49)

(100.00)

(15731.49)

—

0.396

FCF / Net incomex

—

1.527

0.815

0.510

0.892

—

0.854

—

(79.81)

ROIC%

—

(560.25)

(1058.11)

(53.41)

(17.10)

(1.10)

(306.83)

—

(203.30)

Return on equity%

—

(533.51)

(497.87)

—

(80.21)

(1.60)

(497.87)

—

(55.37)

Return on assets%

—

(268.94)

(229.47)

(21.14)

(13.17)

(0.43)

(125.31)

—

(3.19)

EPS$

—

(1,222)

(140.88)

(15.77)

(3.95)

(0.10)

—

EPS growth%

—

88.47

88.80

74.93

97.49

88.47

—

1.57

Bookvalue per sh$

—

229.09

32.14

(3.39)

12.26

6.19

(62.32%)

—

(1.27)

FCF per share$

—

(1,867)

(114.86)

(8.05)

(3.53)

(0.10)

—

Dividend per sh$

—

Div yield (avg)%

—

Payout ratio%

—

1.617

Shares (diluted)M

—

0.012

0.112

1.145

1.617

◌1.617

413.07%

—

Buyback yield%

—

(836.62)

(921.27)

(41.20)

◌—

(836.62)

—

0.137

D/E ratiox

—

0.322

0.229

—

0.095

0.138

0.162

—

13.55

Enterprise value$M

—

9.267

0.744

67.19

8.775

13.15

(1.80%)

—

LT debt$M

—

Peers (US$34.84M)

Cap (US$)

IXICO plc

39.28M

—

Sareum Holdings plc

33.02M

—

ImmuPharma plc

27.68M

—

INmune Bio Inc.

34.75M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

—

(750.2)

Own earn%

—

Sh yield%

—

(836.62)

Owners

Insiders/Inst%

23.96

9.15

Short interest%

1.84

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

—

EPS growth years

3/3

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.

Growth vs revenue

Latest

Trend

1Y CAGR

Rel growth

Revenue

$0.036M

Cost of revenue

$0.694M

Operating expenses

$6.426M

(58.86%)

Asset mix

Trend

Goodwill & intangibles

94.65%

Other

3.49%

Cash and investments

1.85%

Reinvestment returns

No breakdown available